DOI QR코드

DOI QR Code

Association Between ERCC2 Polymorphisms and Glioma Risk: a Meta-analysis

  • Huang, Li-Ming (Department of Chemotherapy, The First Affiliated Hospital, Fujian Medical University) ;
  • Shi, Xi (Department of Chemotherapy, The First Affiliated Hospital, Fujian Medical University) ;
  • Yan, Dan-Fang (Department of Radiation Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University) ;
  • Zheng, Min (Department of Chemotherapy, The First Affiliated Hospital, Fujian Medical University) ;
  • Deng, Yu-Jie (Department of Chemotherapy, The First Affiliated Hospital, Fujian Medical University) ;
  • Zeng, Wu-Cha (Department of Chemotherapy, The First Affiliated Hospital, Fujian Medical University) ;
  • Liu, Chen (Department of Chemotherapy, The First Affiliated Hospital, Fujian Medical University) ;
  • Lin, Xue-De (Department of Chemotherapy, The First Affiliated Hospital, Fujian Medical University)
  • Published : 2014.06.15

Abstract

ERCC2 is an essential component of the nucleotide excision repair pathway which is involved in the effective maintenance of genome integrity. Association studies on ERCC2 polymorphisms and glioma risk have yielded inconclusive results. This meta-analysis was performed to gain a better insight into the relationship between ERCC2 polymorphisms and glioma risk. A systematic literature search updated to December 2, 2013 was performed in the Pubmed and EMBASE databases. Crude pooled odds ratios (ORs) with their corresponding 95% confidence intervals (95% CIs) were used to estimate the association between ERCC2 polymorphisms and glioma risk under a suitable effect model according to heterogeneity. All analyses were performed using Review Manager 5 (version 5.2) and STATA (version 12.0). The combined results demonstrated rs13181 to be significantly associated with glioma risk (G allele versus T allele: OR=1.15, 95% CI=1.05-1.26, P=0.002; dominant model: OR=1.22, 95% CI=1.07-1.39, P=0.002; recessive model: OR=1.18, 95% CI=0.98-1.41, P=0.070). We also found that rs13181 acts in an allele dose-dependent manner (GG versus TT: OR=1.30, 95% CI=1.07-1.57, P=0.009; TG versus TT: OR=1.20, 95%=CI 1.05-1.37, P=0.009; trend test, P=0.004). However, no evidence was found in analyses for the association between other 3 ERCC2 polymorphisms (rs238406, rs1799793, and rs1052555) and susceptibility to glioma development. Our meta-analysis suggests that rs13181 is significantly associated with glioma risk in an allele dose-dependent manner, whereas, 3 other ERCC2 polymorphisms (rs238406, rs1799793, and rs1052555) may have no influence.

Keywords

References

  1. Caggana M, Kilgallen J, Conroy JM, et al (2001). Associations between ERCC2 polymorphisms and gliomas. Cancer Epidemiol Biomarkers Prev, 10, 355-60.
  2. Chen DQ, Yao DX, Zhao HY, Yang SJ (2012). DNA repair gene ERCC1 and XPD polymorphisms predict glioma susceptibility and prognosis. Asian Pac J Cancer Prev, 13, 2791-4. https://doi.org/10.7314/APJCP.2012.13.6.2791
  3. Coin F, Bergmann E, Tremeau-Bravard A, Egly JM (1999). Mutations in XPB and XPD helicases found in xeroderma pigmentosum patients impair the transcription function of TFIIH. EMBO J, 18, 1357-66. https://doi.org/10.1093/emboj/18.5.1357
  4. de Laat WL, Jaspers NG, Hoeijmakers JH (1999). Molecular mechanism of nucleotide excision repair. Genes Dev, 13, 768-85. https://doi.org/10.1101/gad.13.7.768
  5. Duan XL, Gong H, Zeng XT, et al (2012). Association between XPD Asp312Asn polymorphism and esophageal cancer susceptibility: a meta-analysis. Asian Pac J Cancer Prev, 13, 3299-303. https://doi.org/10.7314/APJCP.2012.13.7.3299
  6. Guo LY, Jin XP, Niu W, et al (2012). Association of XPD and XRCC1 genetic polymorphisms with hepatocellular carcinoma risk. Asian Pac J Cancer Prev, 13, 4423-6. https://doi.org/10.7314/APJCP.2012.13.9.4423
  7. Hoeijmakers JH (2009). DNA damage, aging, and cancer. N Engl J Med, 361, 1475-85. https://doi.org/10.1056/NEJMra0804615
  8. Lehmann AR (2001). The xeroderma pigmentosum group D (XPD) gene: one gene, two functions, three diseases. Genes Dev, 15, 15-23. https://doi.org/10.1101/gad.859501
  9. Liang BC, Ross DA, Reed E (1995). Genomic copy number changes of DNA repair genes ERCC1 and ERCC2 in human gliomas. J Neurooncol, 26, 17-23. https://doi.org/10.1007/BF01054765
  10. Liu Y, Scheurer ME, El-Zein R, et al (2009). Association and interactions between DNA repair gene polymorphisms and adult glioma. Cancer Epidemiol Biomarkers Prev, 18, 204-14. https://doi.org/10.1158/1055-9965.EPI-08-0632
  11. Luo KQ, Mu SQ, Wu ZX, et al (2013). Polymorphisms in DNA repair genes and risk of glioma and meningioma. Asian Pac J Cancer Prev, 14, 449-52. https://doi.org/10.7314/APJCP.2013.14.1.449
  12. McKean-Cowdin R, Barnholtz-Sloan J, Inskip PD, et al (2009). Associations between polymorphisms in DNA repair genes and glioblastoma. Cancer Epidemiol Biomarkers Prev, 18, 1118-26. https://doi.org/10.1158/1055-9965.EPI-08-1078
  13. Moher D, Liberati A, Tetzlaff J, Altman DG (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol, 62, 1006-12. https://doi.org/10.1016/j.jclinepi.2009.06.005
  14. Moisan F, Laroche-Clary A, Auzanneau C, et al (2012). Deciphering the role of the ERCC2 gene polymorphism on anticancer drug sensitivity. Carcinogenesis, 33, 962-8. https://doi.org/10.1093/carcin/bgs107
  15. Ohgaki H, Kleihues P (2005). Epidemiology and etiology of gliomas. Acta Neuropathol, 109, 93-108. https://doi.org/10.1007/s00401-005-0991-y
  16. Qiao Y, Spitz MR, Shen H, et al (2002). Modulation of repair of ultraviolet damage in the host-cell reactivation assay by polymorphic XPC and XPD/ERCC2 genotypes. Carcinogenesis, 23, 295-9. https://doi.org/10.1093/carcin/23.2.295
  17. Rajaraman P, Hutchinson A, Wichner S, et al (2010). DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma. Neuro Oncol, 12, 37-48. https://doi.org/10.1093/neuonc/nop012
  18. Salnikova LE, Belopolskaya OB, Zelinskaya NI, Rubanovich AV (2013). The potential effect of gender in CYP1A1 and GSTM1 genotype-specific associations with pediatric brain tumor. Tumour Biol, 34, 2709-19. https://doi.org/10.1007/s13277-013-0823-y
  19. Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M (2006). Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol, 2, 494-503; quiz 1 p following 16.
  20. Smith JS, Tachibana I, Pohl U, et al (2000). A transcript map of the chromosome 19q-arm glioma tumor suppressor region. Genomics, 64, 44-50. https://doi.org/10.1006/geno.1999.6101
  21. Sung P, Bailly V, Weber C, et al (1993). Human xeroderma pigmentosum group D gene encodes a DNA helicase. Nature, 365, 852-5. https://doi.org/10.1038/365852a0
  22. Wlodarczyk M, Nowicka G (2012). XPD gene rs13181 polymorphism and DNA damage in human lymphocytes. Biochem Genet, 50, 860-70. https://doi.org/10.1007/s10528-012-9526-0
  23. Wood RD, Mitchell M, Sgouros J, Lindahl T (2001). Human DNA repair genes. Science, 291, 1284-9. https://doi.org/10.1126/science.1056154
  24. Wrensch M, Kelsey KT, Liu M, et al (2005). ERCC1 and ERCC2 polymorphisms and adult glioma. Neurol Oncol, 7, 495-507. https://doi.org/10.1215/S1152851705000037
  25. Xu Z, Ma W, Gao L, Xing B (2013). Association between ERCC1 C8092A and ERCC2 K751Q polymorphisms and risk of adult glioma: a meta-analysis. Tumour Biol, [Epub ahead of print].
  26. Yang P, Kollmeyer TM, Buckner K, et al (2005). Polymorphisms in GLTSCR1 and ERCC2 are associated with the development of oligodendrogliomas. Cancer, 103, 2363-72. https://doi.org/10.1002/cncr.21028
  27. Yong WH, Chou D, Ueki K, et al (1995). Chromosome 19q deletions in human gliomas overlap telomeric to D19S219 and may target a 425 kb region centromeric to D19S112. J Neuropathol Exp Neurol, 54, 622-6. https://doi.org/10.1097/00005072-199509000-00002
  28. Zintzaras E (2010). Impact of Hardy-Weinberg equilibrium deviation on allele-based risk effect of genetic association studies and meta-analysis. Eur J Epidemiol, 25, 553-60. https://doi.org/10.1007/s10654-010-9467-z

Cited by

  1. Association between common polymorphisms in ERCC gene and glioma risk vol.96, pp.20, 2017, https://doi.org/10.1097/MD.0000000000006832